Jubilant Ingrevia Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Jubilant Ingrevia Ltd filed with BSE on 27 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jubilant Ingrevia reported Q1 FY27 revenue of Rs 1,300 crore, up 25% year-on-year, with EBITDA of Rs 209 crore, up 36% year-on-year and 22% sequentially, and PAT of Rs 106 crore, up 41% year-on-year. Management attributed the growth to Specialty Chemicals, Nutrition and a rebound in Chemical Intermediates, along with progress on its CDMO and Fine Chemicals pipeline. Management maintained its full-year EBITDA guidance of Rs 750 crore to Rs 800 crore while citing volatility in the large CDMO contract's volume visibility.
Numbers mentioned
Revenue: INR1,300 crore (Q1 FY27)
p. 5
“Q1 marked a strong start to the year with revenue reaching a 15-quarter high of INR1,300 crore, up 25% year-on-year, driven by healthy volume growth and improved realizations.”
Deepak Jain, page 5 of the filed PDF · View the filing
EBITDA: INR209 crore (Q1 FY27)
p. 5
“EBITDA increased to INR209 crore, growing 36% year-on-year and 22% sequentially, while PAT stood at INR106 crore, up 41% year-on-year and 22% quarter-on-quarter.”
Deepak Jain, page 5 of the filed PDF · View the filing
Specialty Chemicals revenue: INR533 crore (Q1 FY27)
p. 5
“In our Specialty Chemicals business, we delivered revenue of INR533 crore, up 11% year-on-year and 3% sequentially, supported by steady business volumes and robust growth in Fine Chemicals and CDMO businesses.”
Deepak Jain, page 5 of the filed PDF · View the filing
Specialty Chemicals EBITDA margin: 26% (Q1 FY27)
p. 5
“EBITDA stood at INR139 crore with margins of 26%, benefiting from improved pricing and a richer product mix led by value-added CDMO and fine chemical offerings.”
Deepak Jain, page 5 of the filed PDF · View the filing
CDMO and Fine Chemicals pipeline peak revenue potential: INR3,500-plus crore
p. 5
“We have a funnel of 100-plus molecules with INR3,500-plus crore of peak revenue potential with now 25-plus confirmed molecules, which will drive our growth in coming years.”
Deepak Jain, page 5 of the filed PDF · View the filing
Nutrition segment revenue: INR243 crore (Q1 FY27)
p. 6
“In our Nutrition & Health segment, the Nutrition segment continued its strong momentum with revenue growing to INR243 crore, up 36% year-on-year and 6% quarter-on-quarter.”
Deepak Jain, page 6 of the filed PDF · View the filing
Nutrition segment EBITDA: INR36 crore (Q1 FY27)
p. 6
“We achieved the highest EBITDA in the segment over the last 3 years at INR36 crore, reflecting a 45% year-on-year and 12% sequential increase, while margins improved to 15%.”
Deepak Jain, page 6 of the filed PDF · View the filing
Chemical Intermediates revenue: INR524 crore (Q1 FY27)
p. 6
“Revenue in the segment grew to INR524 crore, up 38% year-on-year and 21% quarter-on-quarter, driven by strong volume growth and improved realizations, supported by higher input cost pass-throughs.”
Deepak Jain, page 6 of the filed PDF · View the filing
Chemical Intermediates EBITDA: INR57 crore (Q1 FY27)
p. 6
“EBITDA for the segment stood at INR57 crore, up 240% year-on-year and 163% quarter-on-quarter, driven by strong realization gains across the product portfolio and effective cost pass-through.”
Deepak Jain, page 6 of the filed PDF · View the filing
Lean savings target: INR100 crore (FY27)
p. 6
“we remain firmly on track, targeting INR100 crore of lean savings in FY27.”
Deepak Jain, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Full year EBITDA — INR750 crore to INR800 crore · FY27
stated firmly by Varun Gupta
p. 11
“Regarding your first point, whether we want to upgrade our guidance, we would like to stick with the same guidance of INR750 crore to INR800 crore.”
Varun Gupta, page 11 of the filed PDF · View the filing
First half EBITDA — roughly INR400 crore plus · H1 FY27
stated firmly by Varun Gupta
p. 11
“Sequential growth will be there. It will be in the similar range of what we have indicated when we met in the Bharuch a month back of roughly INR200 crore kind of an EBITDA in the first half will be around INR400 crore plus.”
Varun Gupta, page 11 of the filed PDF · View the filing
EBITDA — coming quarters
stated as an aspiration by Shyam Bhartia
p. 4
“We anticipate sequential improvement in revenue and EBITDA over the coming quarters.”
Shyam Bhartia, page 4 of the filed PDF · View the filing
Multipurpose plant commissioning — end of current calendar year
stated firmly by Shyam Bhartia
p. 4
“In the new multipurpose plant remains on track for commissioning by the end of current calendar year, further strengthening of our CDMO and Fine Chemicals growth road map.”
Shyam Bhartia, page 4 of the filed PDF · View the filing
Niacinamide plant utilization — 70% of the peak volumes · coming quarters
stated as an aspiration by Deepak Jain
p. 9
“And we are hoping in coming quarters, we will be able to take it to 70% of the peak volumes very soon.”
Deepak Jain, page 9 of the filed PDF · View the filing
Sequential EBITDA improvement — Q2 FY27
stated conditionally by Deepak Jain
p. 9
“So if that continues, then we should be a sequential improvement in EBITDA coming quarters.”
Deepak Jain, page 9 of the filed PDF · View the filing
Large CDMO contract volume clarity — next month
stated conditionally by Deepak Jain
p. 19
“So we are hopeful we will get more visibility at least about next quarter by next month.”
Deepak Jain, page 19 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the plant ran smoothly, full volumes were not served due to a temporary pause requested by the innovator over raw material price escalation, and the contract made positive EBITDA reflected in Q1.
Answered by Deepak Jain
Asked by Siddharth Gadekar: What was the contribution of the large CDMO contract this quarter and did lower utilization cause an EBITDA loss on the plant?
p. 8
“We did not serve the full volumes last quarter as the innovator had confirmed because in between the raw material prices had escalated due to war and the innovator asked us to take a temporary pause till pricing came down.”
Deepak Jain, page 8 of the filed PDF · View the filing
Management said prior EBITDA expectations are maintained and that they have downside protection if volumes don't come through.
Answered by Deepak Jain
Asked by Siddharth Gadekar: How should the full year EBITDA on the large contract be viewed if full volumes do not materialize?
p. 8
“But in the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets.”
Deepak Jain, page 8 of the filed PDF · View the filing
Management said guidance would remain unchanged despite expected sequential growth.
Answered by Varun Gupta
Asked by Abhijit Akella: Given Q1 EBITDA and expected sequential growth, would the company upgrade full-year guidance?
p. 11
“we would like to stick with the same guidance of INR750 crore to INR800 crore.”
Varun Gupta, page 11 of the filed PDF · View the filing
Management said the impact would be minimal due to careful inventory management and finished goods prices not falling as much as feared, and even rising again due to renewed conflict.
Answered by Deepak Jain
Asked by Nitesh Dhoot: Does the expected fade of Q1 nutrition inventory benefits into Q2 still hold?
p. 15
“So because of these three factors, we feel the impact coming from any inventory being carried over from Q1 to Q2 will be very minimal on the business.”
Deepak Jain, page 15 of the filed PDF · View the filing
Management confirmed volumes would be higher in the current quarter.
Answered by Deepak Jain
Asked by Harsh Shah: Will volumes for the large CDMO contract be higher this quarter than the previous one?
p. 17
“Yes, Harsh, the volumes in this quarter will be more than the previous quarter.”
Deepak Jain, page 17 of the filed PDF · View the filing
Management reiterated they have full protection on the contract.
Answered by Deepak Jain
Asked by Rohit Nagraj: Is there a take-or-pay commitment on the $300 million CDMO contract, and could it extend beyond 5 years if commitments fall short?
p. 20
“Yes, we have full protection.”
Deepak Jain, page 20 of the filed PDF · View the filing
Risks flagged
Innovator customer paused volumes on the large CDMO contract due to raw material price escalation from the war
p. 8
“the innovator asked us to take a temporary pause till pricing came down.”
Deepak Jain, page 8 of the filed PDF · View the filing
Lack of finalized volume visibility from the large CDMO contract customer
p. 8
“They have not finalized and hence, I cannot provide any further visibility.”
Deepak Jain, page 8 of the filed PDF · View the filing
Volatility in the Acetyls/chemical intermediates market could reverse gains
p. 11
“But given the volatility which exists in the market, particularly on the Acetyl segment, we never know what happens in Q4.”
Deepak Jain, page 11 of the filed PDF · View the filing
Pricing pressure in commoditized pyridine variants due to overcapacity in China
p. 16
“There are some commoditized variants of Pyridine, including the building block itself. The pricing pressure is more acute there because of the overcapacity in China.”
Deepak Jain, page 16 of the filed PDF · View the filing
Rise in power and fuel costs due to the Gulf crisis increasing natural gas costs
p. 18
“Second, because of this Gulf crisis, the cost of LSHS or the natural gas has also gone up, which has led to the increase in the cost of power, which is fuel, which is reflected in our P&L.”
Varun Gupta, page 18 of the filed PDF · View the filing
Increase in domestic and international logistics costs
p. 18
“bulk of the increase is due to the logistic cost where we have been hit by the increase in the cost of logistics, both domestic and international, which is reflected there”
Varun Gupta, page 18 of the filed PDF · View the filing
B3 pricing is historically volatile and could decline by end of Q2
p. 16
“There is a possibility that prices may start to come down by end of Q2 based on historical trends.”
Deepak Jain, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.